9 Sources of evidence

The following documentation and opinion was made available to the Committee:

Assessment report:

  • prepared by Wessex Institute for Health Research and Development, University of Southampton (The effectiveness and cost effectiveness of temozolomide for the treatment of recurrent malignant glioma, November 2000).

Manufacturer or sponsor submissions:

  • Schering Plough UK Ltd

Professional or specialist group, patient or carer group and trade association submissions:

  • Royal College of Physicians and the Royal College of Radiologists (joint)

  • MRC Clinical Trials Unit

  • Royal College of General Practitioners

  • Royal College of Surgeons of England

  • Association of British Neurologists and the Royal College of Physicians (joint)

External expert and patient advocate submissions:

  • Dr Paul Symonds, Reader and Consultant in Clinical Oncology, University of Leicester

  • Douglas Guerrero, Clinical Nurse Specialist, Neuro‑Oncology, Royal Marsden Hospital

  • Dr Mike Brada, Reader and Consultant in Clinical Oncology, Royal Marsden Hospital